Travere Therapeutics
Yahoo Finance • 11 days ago
Target initiated, Nike upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: RBC Capital upgraded Nike (NKE) to Out... Full story
Yahoo Finance • 14 days ago
Implied FYX Analyst Target Price: $122
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story
Yahoo Finance • 18 days ago
Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside
We recently published AI Frenzy: 10 Stocks Crushing the Market, 6 Climb to Fresh Highs. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the top performers on Wednesday. Travere Therapeutics, Inc. (NASDAQ:TVTX) soared to a new all-time... Full story
Yahoo Finance • 19 days ago
Notable Wednesday Option Activity: MCD, DAKT, TVTX
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in McDonald's Corp (Symbol: MCD), where a total of 16,370 contracts have traded so far, representing approximately 1.6 million underl... Full story
Yahoo Finance • 2 months ago
Notable Wednesday Option Activity: TVTX, EL, SMR
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Travere Therapeutics Inc (Symbol: TVTX), where a total volume of 8,102 contracts has been traded thus far today, a contra... Full story
Yahoo Finance • 2 months ago
Travere Therapeutics price target raised to $32 from $30 at Wedbush
Wedbush raised the firm’s price target on Travere Therapeutics (TVTX) to $32 from $30 and keeps an Outperform rating on the shares. The firm notes Q2 update represented another strong showing for Filspari with Travere reporting a Filspari... Full story
Yahoo Finance • 2 months ago
Travere Therapeutics Inc (NASDAQ:TVTX) Surpasses Q2 2025 Expectations with Strong Revenue Growth and Narrower Loss
Travere Therapeutics Inc (NASDAQ:TVTX [https://www.chartmill.com/stock/quote/TVTX]) reported second-quarter 2025 financial results that exceeded analyst expectations, prompting a positive market reaction. The company posted revenue of $114... Full story
Yahoo Finance • 3 months ago
Exploring 3 High Growth Tech Stocks In The US Market
The U.S. market is currently experiencing a mix of volatility and optimism, with investor sentiment being influenced by renewed tariff threats and record highs in major indices like the S&P 500 and Nasdaq Composite. In this environment, id... Full story
Yahoo Finance • 3 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at... Full story
Yahoo Finance • 3 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton a... Full story
Yahoo Finance • 4 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton a... Full story
Yahoo Finance • 4 months ago
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3 NICE's recommendation is based on clinically meaningful results from the phase-III PROTE... Full story
Yahoo Finance • 5 months ago
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation from Committee for Medicinal Products fo... Full story
Yahoo Finance • 6 months ago
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney... Full story
Yahoo Finance • 7 months ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate... Full story
Yahoo Finance • 7 months ago
Travere Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences in March: TD Cowen 45th Annual Health Care Co... Full story
Yahoo Finance • 7 months ago
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGS Net product sales of FILSPARI totaled $50 million in 4Q 2024; $132 million for full year 2024 Net product sales totaled $74... Full story
Yahoo Finance • 7 months ago
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financi... Full story
Yahoo Finance • 8 months ago
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated for FSGS, a rare kidney disorder and l... Full story
Yahoo Finance • 11 months ago
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ST. GALLEN, Switzerland and SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- CSL Vifor and Travere Therapeu... Full story
